Bexarotene Gel (Targretin®)
Bexarotene is a retinoid, a type of synthetic vitamin A, used in the treatment of early stage CTCL (Stage I-A, I-B, and II-A). Bexarotene activates a specific type of retinoid receptor (known as RXR) and influences cell growth and differentiation. Bexarotene gel is applied to affected lesions between 1-4 times per day. Upon initial use of bexarotene gel, patients frequently experience varying degrees of increased redness, scaling or itching at treatment sites or beyond the borders. These local side effects can be reduced by gradual increase in frequency of application or combination use of topical steroids. Treatment may last from 16 to 40 weeks.
For information on Eisai product reimbursement and patient assistance programs (where applicable), please visit www.eisaireimbursement.com
Click here to access a "Frequently Asked Questions" resource on Targretin.
This is an automatic translation service and therefore the
Cutaneous Lymphoma Foundation is not responsible
for any potential translation inaccuracies.